Market Closed -
Japan Exchange
02:00:00 2024-05-07 am EDT
|
5-day change
|
1st Jan Change
|
1,631
JPY
|
-0.55%
|
|
-0.49%
|
+1.75%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,883
|
6,778
|
11,739
|
9,081
|
8,335
|
7,921
|
Enterprise Value (EV)
1 |
12,235
|
11,680
|
16,125
|
13,022
|
12,080
|
10,992
|
P/E ratio
|
16.4
x
|
18.3
x
|
14
x
|
10.5
x
|
10.1
x
|
11.3
x
|
Yield
|
2.13%
|
1.85%
|
1.07%
|
1.38%
|
1.48%
|
2.18%
|
Capitalization / Revenue
|
0.71
x
|
0.79
x
|
1.16
x
|
0.89
x
|
0.79
x
|
0.75
x
|
EV / Revenue
|
1.47
x
|
1.36
x
|
1.59
x
|
1.28
x
|
1.14
x
|
1.04
x
|
EV / EBITDA
|
13.2
x
|
10.1
x
|
9.32
x
|
8.08
x
|
6.79
x
|
7.34
x
|
EV / FCF
|
-5.89
x
|
7.55
x
|
27.6
x
|
58.5
x
|
37.7
x
|
15.7
x
|
FCF Yield
|
-17%
|
13.2%
|
3.62%
|
1.71%
|
2.65%
|
6.36%
|
Price to Book
|
0.61
x
|
0.69
x
|
1.12
x
|
0.82
x
|
0.71
x
|
0.64
x
|
Nbr of stocks (in thousands)
|
5,015
|
5,006
|
5,006
|
5,006
|
4,940
|
4,942
|
Reference price
2 |
1,173
|
1,354
|
2,345
|
1,814
|
1,687
|
1,603
|
Announcement Date
|
3/12/19
|
3/27/20
|
3/29/21
|
3/30/22
|
3/29/23
|
3/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
8,326
|
8,605
|
10,152
|
10,203
|
10,604
|
10,587
|
EBITDA
1 |
927
|
1,156
|
1,730
|
1,612
|
1,779
|
1,498
|
EBIT
1 |
467
|
568
|
1,134
|
946
|
1,185
|
1,008
|
Operating Margin
|
5.61%
|
6.6%
|
11.17%
|
9.27%
|
11.18%
|
9.52%
|
Earnings before Tax (EBT)
1 |
476
|
515
|
1,048
|
1,176
|
1,159
|
978
|
Net income
1 |
358
|
371
|
837
|
862
|
833
|
701
|
Net margin
|
4.3%
|
4.31%
|
8.24%
|
8.45%
|
7.86%
|
6.62%
|
EPS
2 |
71.38
|
74.09
|
167.2
|
172.2
|
167.8
|
141.9
|
Free Cash Flow
1 |
-2,078
|
1,546
|
583.5
|
222.6
|
320.4
|
698.9
|
FCF margin
|
-24.96%
|
17.97%
|
5.75%
|
2.18%
|
3.02%
|
6.6%
|
FCF Conversion (EBITDA)
|
-
|
133.74%
|
33.73%
|
13.81%
|
18.01%
|
46.65%
|
FCF Conversion (Net income)
|
-
|
416.71%
|
69.71%
|
25.83%
|
38.46%
|
99.7%
|
Dividend per Share
2 |
25.00
|
25.00
|
25.00
|
25.00
|
25.00
|
35.00
|
Announcement Date
|
3/12/19
|
3/27/20
|
3/29/21
|
3/30/22
|
3/29/23
|
3/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
6,352
|
4,902
|
4,386
|
3,941
|
3,745
|
3,071
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
6.852
x
|
4.24
x
|
2.535
x
|
2.445
x
|
2.105
x
|
2.05
x
|
Free Cash Flow
1 |
-2,078
|
1,546
|
584
|
223
|
320
|
699
|
ROE (net income / shareholders' equity)
|
3.77%
|
3.83%
|
8.26%
|
7.99%
|
7.27%
|
5.8%
|
ROA (Net income/ Total Assets)
|
1.61%
|
1.91%
|
3.8%
|
3.06%
|
3.69%
|
3.04%
|
Assets
1 |
22,243
|
19,467
|
22,050
|
28,141
|
22,589
|
23,025
|
Book Value Per Share
2 |
1,911
|
1,957
|
2,091
|
2,220
|
2,392
|
2,499
|
Cash Flow per Share
2 |
235.0
|
298.0
|
312.0
|
437.0
|
483.0
|
603.0
|
Capex
1 |
2,478
|
247
|
663
|
237
|
166
|
194
|
Capex / Sales
|
29.76%
|
2.87%
|
6.53%
|
2.32%
|
1.57%
|
1.83%
|
Announcement Date
|
3/12/19
|
3/27/20
|
3/29/21
|
3/30/22
|
3/29/23
|
3/28/24
|
|
1st Jan change
|
Capi.
|
---|
| +1.75% | 52.63M | | +8.50% | 28.33B | | -29.70% | 3.15B | | -14.71% | 2.57B | | +21.58% | 2.55B | | +7.41% | 2.09B | | -3.87% | 2.04B | | +0.56% | 1.53B | | +2.15% | 1.33B | | +23.78% | 1.23B |
Medical Supplies
|